Prof. Qiu Li 李秋
Chief Physician, Professor
Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and biological targeted therapy for gastrointestinal tumors, liver cancer, ovarian cancer, and malignant lymphoma.
Dr. Li holds a medical doctorate and serves as a professor and doctoral supervisor. Previously worked at Sichuan Cancer Hospital and Fudan University Shanghai Cancer Center. As a member of the State Key Laboratory of Biotherapy at West China Hospital, Dr. Li has led projects under the National 973 Program and National Natural Science Foundation, participated in international multicenter clinical trials, and published over 30 papers.
Professional roles
- Member, American Society of Clinical Oncology (ASCO)
- Member, Chinese Society of Clinical Oncology (CSCO)
- Secretary, Tumor Molecular Targeted Therapy Professional Committee, Chinese Society of Biomedical Engineering
- Executive Physician, Sorafenib Liver Cancer Patient Assistance Project, China Charity Federation
Name order: in Chinese the family name comes first (Li Qiu). Papers usually list the name as Qiu Li or Li Q.
Selected publications
186 papers on PubMed matched by name and affiliation; 87 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Endocrinol (Lausanne), 2026 (senior author): Distribution characteristics of initial lesion sites for diabetic foot ulcers in China: a national multicenter survey. PubMed 42984519
- Int J Surg, 2026 (senior author): Comparative predictive value of immunotherapy biomarkers: a systematic review and network meta-analysis. PubMed 41427504
- Front Public Health, 2025 (senior author): Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis. PubMed 41602061
- Front Public Health, 2025 (senior author): Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy. PubMed 40385627
- Int J Dermatol, 2024 (senior author): Evidence for a causal relationship between immune cells and cutaneous melanoma: a Mendelian randomization study. PubMed 38876468
- Hum Gene Ther, 2024 (senior author): Matrix Protein of Vesicular Stomatitis Virus Targets the Mitochondria, Reprograms Glucose Metabolism, and Sensitizes to 2-Deoxyglucose in Glioblastoma. PubMed 39001830
- Ther Adv Med Oncol, 2024 (senior author): Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma. PubMed 39301138
- J Vasc Access, 2024 (senior author): Implantation of an arteriovenous graft through the peripheral vascular access in the presence of superior vena cava stenosis but a patent azygos vein: A case report. PubMed 37655863
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion